BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saif MW. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Opinion on Pharmacotherapy 2016;17:443-56. [DOI: 10.1517/14656566.2016.1127914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Shelar SB, Gawali SL, Barick KC, Kunwar A, Mohan A, Priyadarsini IK, Hassan PA. Electrostatically bound lanreotide peptide - gold nanoparticle conjugates for enhanced uptake in SSTR2-positive cancer cells. Mater Sci Eng C Mater Biol Appl 2020;117:111272. [PMID: 32919636 DOI: 10.1016/j.msec.2020.111272] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
2 Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22-35. [PMID: 29120923 DOI: 10.1097/MED.0000000000000376] [Cited by in Crossref: 37] [Cited by in F6Publishing: 47] [Article Influence: 12.3] [Reference Citation Analysis]
3 Godara A, Siddiqui NS, Byrne MM, Saif MW. The safety of lanreotide for neuroendocrine tumor. Expert Opin Drug Saf 2019;18:1-10. [PMID: 30582380 DOI: 10.1080/14740338.2019.1559294] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
4 Saif MW, Fu J, Smith MH, Weinstein B, Relias V, Daly KP. Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Pancreat Cancer 2018;4:64-71. [PMID: 30788459 DOI: 10.1089/pancan.2018.0013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Masab M, Saif MW. Telotristat ethyl: Proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea. Cancer Chemother Pharmacol. 2017;80:1055-1062. [PMID: 29051994 DOI: 10.1007/s00280-017-3462-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
6 Werner RA, Weich A, Higuchi T, Schmid JS, Schirbel A, Lassmann M, Wild V, Rudelius M, Kudlich T, Herrmann K, Scheurlen M, Buck AK, Kropf S, Wester HJ, Lapa C. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach. Theranostics 2017;7:1489-98. [PMID: 28529632 DOI: 10.7150/thno.18754] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 11.2] [Reference Citation Analysis]
7 Dissanayake S, Denny WA, Gamage S, Sarojini V. Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides. Journal of Controlled Release 2017;250:62-76. [DOI: 10.1016/j.jconrel.2017.02.006] [Cited by in Crossref: 139] [Cited by in F6Publishing: 151] [Article Influence: 27.8] [Reference Citation Analysis]
8 Patel D, Chan D, Cehic G, Pavlakis N, Price TJ. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. Expert Rev Endocrinol Metab 2016;11:311-27. [PMID: 30058926 DOI: 10.1080/17446651.2016.1199952] [Cited by in F6Publishing: 1] [Reference Citation Analysis]